Skip to content

A single arm clinical study :efficacy of kalyanaka guda in the management of the irritable bowel syndrome

A single arm clinical study to evaluate the efficacy of kalyanaka guda in the management of irritable bowel syndrome with special reference to vatika grahani - nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070131
Enrollment
30
Registered
2024-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K582- Mixed irritable bowel syndrome

Interventions

None listed

Sponsors

National Institute of Ayurveda, Deemed to be University, Jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients between the age group of 18 to 60 years. 2.Patients irrespective of sex and socio- economic status. 3.Patients having signs and symptoms (abdominal pain and altered bowel habits) of Irritable Bowel Syndrome and Vatika Grahani like parshvavankshanruk, chiraat dukham drav shushkam tanu..punah punah srujeta varchah..

Exclusion criteria

Exclusion criteria: 1. Mixed infection with parasites like round worms, hook worms etc. 2. Patients with bleeding per rectum. 3. Patients with evidence of malignancy. 4. Patients having concomitant illness like hypertension, diabetes mellitus type II, Amoebic dysentery, Ulcerative colitis, Malabsorption syndrome, Inflammatory Bowel Diseases & Intestinal tuberculosis, Lactase deficiency diarrhoea. 5. Patients suffering from major systemic illness like cancer, crohn’s disease, renal failure etc. 6. Patients who are taking corticosteroids, antidepressants, anticholinergic, or any other drugs that may have an influence on the outcome of study. 7. Alcoholics and drug abusers. 8. Pregnant and lactating women. 9. Patients who have completed participation in any other clinical trial during the past six months.

Design outcomes

Primary

MeasureTime frame
Changes in the intensity of abdominal pain and altered bowel habits.Timepoint: At baseline and end of 28 days of treatment.

Secondary

MeasureTime frame
Changes in the other symptoms(Bloating and Weakness) of IBS. Changes in quality of life. (QOL SF-36)Timepoint: At baseline and end of 28 days of treatment.

Countries

India

Contacts

Public ContactDr Rashmi Mutha

National Institute of Ayurveda, Deemed to be University, Jaipur

rashmimutha21@yahoo.com9413102151

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026